An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, ...

President Trump’s proposed tariffs on Denmark could have costly consequences for Americans relying on GLP-1 medications like Ozempic and Wegovy—and consumers are becoming increasingly concerned. While ...

A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

We recently compiled a list of the 12 Best Booming Stocks to Invest in Now. In this article, we are going to take a look at ...

More and more people are taking weight loss injectables like Wegovy — but not everyone prescribed these drugs should have ...

A multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded ...

Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.